Buy Like Buffett
Watchlist

Flagship explainer

How PURE Bioscience, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$2.2M · 100%Cost of revenue$899000 · 41%Gross profit$1.3M · 59%Operating income−$2.3M · −103%Income before tax−$2.4M · −109%Income tax$0 · 0%Net income−$2.4M · −109%As of 2025-07-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$2.2M100%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
Cost of revenue$89900041%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
$1.3M59%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
−$2.3M−103%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
Income before tax−$2.4M−109%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
Income tax$00%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
−$2.4M−109%
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
Source:
  • 10-K · FY 2025Filing detailsAccession 0001493152-25-020065 · filed Oct 29, 2025
· event Jul 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full PURE Bioscience, Inc. analysis at Buy Like Buffett